Peer-influenced content. Sources you trust. No registration required. This is HCN.

ReachMDClinician’s Update on Omega-3s in ASCVD Risk Reduction

More than 15 professional societies now recommend the use of icosapent ethyl to treat ASCVD, but clinical questions about the use of omega-3 fatty acids remain. Drs. Leslie Cho and Erin Michos discuss the role of DHA and EPA and whether all omega-3 fatty acids are the same. But what about EPA plasma levels, incidence of atrial fibrillation, and differences between the STRENGTH and REDUCE-IT trials? Tune in to get these answers and more in this 13-minute, 0.25-CME credit hours video podcast.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form